Urinary concentrations of 15-epimer of lipoxin A 4 are lower in patients with aspirin-intolerant compared with aspirin-tolerant asthma

Clinical and Experimental Allergy

Volumn 41, Issue 12, 2011, Pages 1711-1718

  Yamaguchi, H ^a,b   Higashi, N ^a   Mita, H ^a   Ono, E ^a   Komase, Y ^b   Nakagawa, T ^c   Miyazawa, T ^b   Akiyama, K ^a   Taniguchi, M ^a  

^a SAGAMIHARA NATIONAL HOSPITAL   (Japan)

^b ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Kawazoe Clinic   (Japan)

Author keywords

15 epimer of lipoxin A 4; Aspirin intolerant asthma; Asthma severity; Leukotriene E 4; Lipoxin A 4

Indexed keywords

LEUKOTRIENE E4; LIPOXIN A; PEPTIDOLEUKOTRIENE;

ADULT; ARTICLE; ASPIRIN EXACERBATED RESPIRATORY DISEASE; ASTHMA; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME IMMUNOASSAY; EPIMER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY CONCENTRATING CAPACITY; PRIORITY JOURNAL;

ADULT; AGED; ASPIRIN; ASTHMA, ASPIRIN-INDUCED; FEMALE; HUMANS; LEUKOTRIENE E4; LIPOXINS; MALE; MIDDLE AGED; ROC CURVE;

EID: 82155165846     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2011.03839.x     Document Type: Article

References (32)

1. Stevenson DD, Szczeklik A. Clinical and pathologic perspectives on aspirin sensitivity and asthma. J Allergy Clin Immunol 2006; 118:773-86.
2. The ENFUMOSA Study Group. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Network for Understanding Mechanisms of Severe Asthma. Eur Respir J 2003; 22:397-8.
3. Dolan CM, Fraher KE, Bleecker ER et al. Design and baseline characteristics of the Epidemiology and Natural History of Asthma: outcomes and Treatment Regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol 2004; 92:32-9.
4. Moore WC, Bleecker ER, Curran-Everett D et al. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. J Allergy Clin Immunol 2007; 119:405-13.
5. Mita H, Endoh S, Kudoh M et al. Possible involvement of mast-cell activation in aspirin provocation of aspirin-induced asthma. Allergy 2001; 56:1061-7.
6. 4 glucuronide concentration in patients with aspirin-intolerant asthma after intravenous aspirin challenge. Clin Exp Allergy 2004; 34:1262-9.
7. Higashi N, Mita H, Ono E et al. Profile of eicosanoid generation in aspirin-intolerant asthma and anaphylaxis assessed by new biomarkers. J Allergy Clin Immunol 2010; 125:1084-91.
8. Mastalerz L, Sanak M, Gawlewicz-Mroczka A, Gielicz A, Cmiel A, Szczeklil A. Prostaglandin E2 systemic production in patients with asthma with and without aspirin hypersensitivity. Thorax 2008; 63:27-34.
9. Sanak M, Levy BD, Clish CB et al. Aspirin-tolerant asthmatics generate more lipoxins than aspirin-intolerant asthmatics. Eur Respir J 2000; 16:44-9.
10. Levy BD, Bonnans C, Silverman ES et al. Diminished lipoxin biosynthesis in severe asthma. Am J Respir Crit Care Med 2005; 172:824-30.
11. Çelik GE, Erkekol FO, Mιsιrlιgil Z, Melli M. Lipoxin A4 levels in asthma: relation with disease severity and aspirin sensitivity. Clin Exp Allergy 2007; 37:1494-501.
12. 4, an endogenous anti-inflammatory compound. J Allergy Clin Immunol 2005; 115:55-60.
13. 4 receptor expression are decreased in severe asthma. Am J Respir Crit Care Med 2008; 178:574-82.
14. Serhan CN. Lipoxins and novel aspirin-triggered 15-epi-lipoxins (ATL): a jungle of cell-cell interactions or a therapeutic opportunity? Prostaglandins 1997; 53:107-37.
15. Fierro IM, Serhan CN. Mechanisms in anti-inflammation and resolution: the role of lipoxins and aspirin-triggered lipoxins. Braz J Med Biol Res 2001; 34:555-66.
16. 4 ELISA. J Pharmacol Exp Ther 1998; 287:779-90.
17. Picado C, Fernandez-Morata JC, Juan M et al. Cyclooxygenase-2 mRNA is downexpressed in nasal polyps from aspirin-sensitive asthmatics. Am J Respir Crit Care Med 1999; 160:291-6.
18. Pierzchalska M, Soja J, Woś M et al. Deficiency of cycloxygenase transcripts in cultured primary bronchial epithelial cells of aspirin-sensitive asthmatics. J Physiol Pharmacol 2007; 58:207-18.
19. (4) and related compounds: development of new extraction techniques for lipoxins. Lab Invest 2002; 82:1253-4.
20. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma: this official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986. Am Rev Respir Dis 1987; 136:225-44.
21. 4: extraction using an Empore C18 disk cartridge. J Chromatogr B Biomed Sci Appl 1997; 692:461-6.
22. 4 12-hydroxydehydrogenase in inflammation. J Biol Chem 2000; 275:25372-80.
23. 4 elimination and metabolism in man. J Allergy Clin Immunol 1990; 85:3-9.
24. Awad JA, Morrow JD, Takahashi K, Roberts LJ 2nd. Identification of non-cyclooxygenase-derived prostanoid (F2-isoprostane) metabolites in human urine and plasma. J Biol Chem 1993; 268:4161-9.
25. 2 alpha is generated from the isoprostane pathway and not the cyclooxygenase in humans. J Biol Chem 2007; 282:329-36.
26. Pérez-Novo CA, Watelet JB, Claeys C, Van Cauwenberge P, Bachert C. Prostaglandin, leukotriene, and lipoxin balance in chronic rhinosinusitis with and without nasal polyposis. J Allergy Clin Immunol 2005; 115:1189-96.
27. Bylund J, Ericsson J, Oliw EH. Analysis of cytochrome P450 metabolites of arachidonic and linoleic acids by liquid chromatography-mass spectrometry with ion trap MS. Anal Biochem 1998; 265:55-68.
28. 4 excretion (hyperleukotrienuria): involvement of chronic hyperplastic rhinosinusitis with nasal polyposis. J Allergy Clin Immunol 2004; 113:277-83.
29. 4 stable analogs reduce allergic airway responses via mechanisms distinct from CysLT1 receptor antagonism. FASEB J 2007; 21:3877-84.
30. Bannenberg G, Moussignac RL, Gronert K et al. Lipoxins and novel 15-epi-lipoxin analogs display potent anti-inflammatory actions after oral administration. Br J Pharmacol 2004; 143:43-52.
31. (4). Nat Med 2002; 8:1018-23.
32. 4 from alveolar macrophages in severe asthma. Respir Res 2010; 11:71-9.